

# Inverse Relationship between APC Gene Mutation in Gastric Adenomas and Development of Adenocarcinoma

Jae-Hyuk Lee,\* Susan C. Abraham,<sup>†</sup>  
Hyun-Soo Kim,<sup>‡</sup> Jong-Hee Nam,<sup>§</sup> Chan Choi,<sup>§</sup>  
Min-Cheol Lee,<sup>§</sup> Chang-Soo Park,<sup>§</sup>  
Sang-Woo Juhng,<sup>§</sup> Asif Rashid,\*  
Stanley R. Hamilton,\* and Tsung-Teh Wu\*

From the Department of Pathology,\* MD Anderson Cancer Center, Houston, Texas; the Department of Pathology, The Johns Hopkins University School of Medicine,<sup>†</sup> Baltimore, Maryland; and the Departments of Internal Medicine<sup>‡</sup> and Pathology,<sup>§</sup> Chonnam National University Medical School, Kwangju, South Korea

**Gastric cancer is common among the world, but genetic mechanisms of gastric carcinogenesis are not well understood. Gastric polypoid adenomas and flat dysplasias are regarded as precursor lesions. However, a detailed molecular study of these lesions has not been done to determine their role as precancerous lesions. We investigated mutations of the APC,  $\beta$ -catenin, and K-ras genes, and microsatellite instability (MSI) status in 35 adenomas and 47 flat dysplasias without adenocarcinoma, 35 adenomas/dysplasias associated with adenocarcinomas, and 39 adenocarcinomas (20 diffuse type and 19 intestinal type). Somatic APC gene mutations were identified in 76% (59 of 78) of adenomas or flat dysplasias without associated adenocarcinoma, but in only 3% (1 of 30) of adenomas/dysplasias associated with adenocarcinoma, and in only 4% (3 of 69) of adenocarcinomas ( $P < 0.000001$ ). No mutations of  $\beta$ -catenin were found in adenocarcinomas, or adenomas/dysplasia without APC mutation. K-ras mutations were detected in 5% (4 of 82) of gastric adenomas/dysplasia without carcinoma, 3% (1 of 39) of adenocarcinomas without associated adenoma/dysplasia, and not in 32 adenocarcinomas with associated adenoma/dysplasia. High level of MSI (MSI-H) was more frequent in gastric adenoma/dysplasia associated with carcinoma (17%, 6 of 35) than in adenomas/dysplasia without carcinoma (3%, 2 of 75;  $P = 0.01$ ). MSI-H was also more frequent in intestinal type adenocarcinoma (20%, 11 of 54) than in diffuse type (0%, 0 of 20;  $P = 0.03$ ). APC gene mutations were present in six of nine (67%) of gastric adenomas/dysplasias with low level of MSI, but in none of the eight adenomas/dysplasia with MSI-H phenotype ( $P = 0.009$ ). Our results indicate that somatic mutation of the APC gene plays an im-**

**portant role in the pathogenesis of gastric adenoma and dysplasia but has a limited role in neoplastic progression to adenocarcinoma. Gastric adenomas or dysplasias without APC mutations but with or without MSI may have a different biological behavior, and are precursors of intestinal-type of gastric adenocarcinomas. (Am J Pathol 2002, 161:611–618)**

Gastric cancer is one of the most common malignant neoplasms among the world. Genetic alterations have been shown to play roles in gastric carcinogenesis including abnormalities in proto-oncogenes (*K-ras* and  $\beta$ -catenin), tumor suppressor genes (*p53* and *APC*), cell-cycle regulator genes (*E-cadherin*), tissue invasion-related genes (*CD44*), and mismatch repair genes (*hMLH1*).<sup>1–13</sup> Gastric adenomas and dysplasias are considered precursor lesion of invasive gastric cancer, but the genetic mechanisms of early gastric carcinogenesis are not well understood.

There are two major histological types of gastric adenocarcinoma (intestinal and diffuse) according to the Lauren classification.<sup>14</sup> The pathogenesis and genetic alterations for these two distinct types of adenocarcinoma are also different.<sup>15–17</sup> The most frequent gastric malignancy is the intestinal type, which is often preceded by sequential steps of precancerous changes, including atrophic gastritis, intestinal metaplasia, and either dysplasia or adenoma. In contrast, the diffuse type of gastric carcinoma tends to arise *de novo* and is infrequently associated with dysplasia or adenoma.<sup>18–21</sup> Abnormal expression and amplification of the *Met* gene, inactivation of the *p53* tumor suppressor gene, abnormal transcription of *CD44*, and loss of telomerase are common events in both types.<sup>15–17,22,23</sup> Reduced or absent expression of *E-cadherin* and *K-sam* gene amplification are unique to the diffuse type gastric adenocarcinoma.<sup>16,17,22</sup> By contrast, *K-ras* mutations, *c-erb2* gene amplification, mutations of the *APC* gene, allelic loss of *BclII* gene and *DCC* locus, and microsatellite instability (MSI, replication error) are preferentially associated with the intestinal-type.<sup>16,17,22</sup> Gastric adenoma (polypoid dysplastic mucosal lesion) and flat dys-

Accepted for publication May 14, 2002.

Address reprint requests to Tsung-Teh Wu, M.D., Ph.D., UT M.D. Anderson Cancer Center, Department of Pathology G1.3595C, Box 85, 1515 Holcombe Blvd., Houston, TX 77030. E-mail: twu@mdanderson.org.

plasia have been regarded as precancerous lesions for intestinal type adenocarcinoma. The sequential accumulation of alternations of *APC* and *K-ras* genes, characteristic of the colorectal adenoma-carcinoma sequence, however, does not frequently occur between adenoma and intestinal-type adenocarcinoma of the stomach.<sup>3-7,24-26</sup>

There are two lines of evidence indicating that not all gastric dysplastic lesions are precursor lesions for gastric carcinoma. First, gastric dysplasia can undergo spontaneous regression clinically, especially low-grade dysplastic lesions.<sup>27,28</sup> Only 11 to 40% of adenoma/dysplasia progress to carcinoma.<sup>29-31</sup> Secondly, *APC* mutations have been reported to occur more frequently in gastric adenomas than in gastric adenocarcinomas.<sup>24-26</sup> However, the *APC* mutation status of gastric adenoma/dysplasia lesions associated with adenocarcinomas has not been studied in detail. It is not clear whether the *APC* gene plays any role in the pathogenesis of adenocarcinomas arising from pre-existing adenoma/dysplasia. Furthermore, genetic alterations separating these two distinct morphological precancerous lesions (flat dysplasia and polypoid adenoma) remain unclear. In this study, we investigated genetic alterations in gastric adenomas, flat dysplasias, adenocarcinoma with associated adenoma/dysplasia, and adenocarcinoma without associated adenoma/dysplasia to determine their potential roles in gastric carcinogenesis.

## Materials and Methods

### Case Selection

This study included 35 adenomas and 47 flat dysplasias from endoscopic biopsies of patients without gastric carcinoma, 39 adenocarcinomas (20 diffuse type and 19 intestinal type) without an associated adenoma/dysplasia, and 35 adenocarcinomas associated with adenoma/dysplasia (29 adenomas/dysplasias were immediately adjacent to the carcinoma, and 6 were distant) from surgical resection specimens (approved by University of Texas MD Anderson Cancer Center Institutional Review Board). All of the cases were retrospectively identified from the surgical pathology files of Chonnam National University Hospital, Kwangju, South Korea between 1996 to 2000. No patient had familial adenomatous polyposis (FAP). The distinction between adenoma and dysplasia was based on endoscopic findings. Gastric adenoma was defined as a polypoid, elevated or exophytic lesion, and flat dysplasia as a flat or depressed lesion. Gastric adenomas and dysplasias were subclassified in hematoxylin and eosin (H&E)-stained slides into low-grade and high-grade dysplasia according to published criteria.<sup>32</sup> The carcinomas were classified histologically according to Lauren<sup>14</sup> and staged according to the criteria of the International Union Against Cancer.<sup>33</sup> Location and size of tumor were also recorded. Gastric nonneoplastic mucosa was evaluated for the presence of intestinal metaplasia, mucosal atrophy by Sydney criteria, and *Helicobacter pylori* by Giemsa stain and Campylobacter-like organism (CLO) test.<sup>34</sup> The clinicopathological features of

patients are summarized in Table 1. Most of adenocarcinomas associated with adenoma/dysplasia were stage 1 tumors and intestinal type carcinomas.

### DNA Extraction

Microdissection from formalin-fixed and paraffin-embedded tissue was performed on H&E-stained slides for both tumor and normal mucosa. A 271/2-gauge needle was used for microdissection of H&E-stained slides under a low-power ( $\times 4$ ) objective. In cases of adenocarcinoma associated with adenoma/dysplasia, carcinoma and adenoma/dysplasia components were separately microdissected and analyzed. Genomic DNA was extracted from microdissected tissue as described previously.<sup>35</sup>

### APC Gene Mutation Analysis

Four sets of oligonucleotide primers (5'-CAGACTTATTGTGTAGAAGA-3' and 5'-CTCCTGAAGAAAATTCAACA-3' for codons 1260 to 1350; 5'-AGGGTTCTAGTTTATCTTCA-3' and 5'-TCTGCTTGGTGGCATGGTTT-3' for codons 1339 to 1436; 5'-GGCATTATAAGCCCCAGTGA-3' and 5'-AAATGCTCATCGAGGCTCA-3' for codons 1417 to 1516; 5'-ACTCCAGATGGATTTTCTTG-3' and 5'-GGCTGGCTTTTTGCTTTAC-3' for codons 1497 to 1596) were used to amplify the mutation cluster region of the *APC* gene for gastrointestinal tumors. Polymerase chain reaction (PCR) was performed under standard conditions in a 50- $\mu$ l volume using PCR Master (Boehringer Mannheim, Mannheim, Germany) and 1  $\mu$ mol/L of both 5' and 3' oligonucleotides with 40 cycles (94°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes). PCR products were purified using shrimp alkaline phosphatase and exonuclease I (Amersham, Buckinghamshire, UK). Purified PCR products were sequenced directly with SequiTherm Excel II DNA Sequencing Kit (Epicentre, Madison, WI) with the same primers used for DNA amplification. Oligonucleotides were end-labeled with [ $\gamma$ -<sup>32</sup>P]-ATP (DuPont-New England Nuclear Research Products, Boston, MA) using T4 polynucleotide kinase (New England Biolabs, Beverly, MA). All mutations were verified in both the sense and anti-sense directions.

### $\beta$ -Catenin Gene Mutation Analysis

Mutation analysis of the  *$\beta$ -catenin* gene was performed only on cases that did not show detectable *APC* mutations. Genomic DNA from each sample was amplified by PCR using the forward primer 5'-ATGGAACCAGACAGAAAAGC-3' and reverse primer 5'-GCTACTTGTCTT-GAGTGAAG-3'. These amplified a 200-bp fragment of exon 3 of the  *$\beta$ -catenin* gene encompassing the region for GSK-3 $\beta$  phosphorylation. PCR reaction was performed under standard conditions in a 50  $\mu$ l volume using PCR Master (Boehringer Mannheim) and 1  $\mu$ mol/L of both 5' and 3' oligonucleotides with 40 cycles (94°C for 1 minute, 58°C for 1 minute, and 72°C for 2 minutes). PCR products were purified and sequenced directly using internal primers (forward, 5'-AAAGCGGCTGTTAGTCACTGG-3'; re-

**Table 1.** Clinicopathological Characteristics of Gastric Adenoma, Dysplasia, and Adenocarcinoma

	Adenocarcinoma (-)		Adenocarcinoma (+)	
	Adenoma	Dysplasia	with Adenoma/dysplasia	without Adenoma/dysplasia
Case no.	35	47	35	39
Age (mean ± SD)	67 ± 9.5	61 ± 8.3	63 ± 8.1	59 ± 11.3
Sex				
Male	28	37	27	22
Female	7	10	8	17
Location				
Body	22	19	17	22
Antrum	13	28	18	17
Size (mm)				
≤10	10	21	9	8
11-20	14	16	12	8
≥21	11	10	14	23
Tumor size (mm)				
Mean ± SD	20.7 ± 15.8	17.8 ± 11.4	21.3 ± 11.1*	35.4 ± 24.8*
Stage				
I			34 <sup>†</sup>	13 <sup>†</sup>
II			1 <sup>†</sup>	4 <sup>†</sup>
III			0 <sup>†</sup>	15 <sup>†</sup>
IV			0 <sup>†</sup>	7 <sup>†</sup>
Histologic grade				
Low grade	24	24		
High grade	11	23		
Histologic subtype				
Intestinal			35 <sup>‡</sup>	19 <sup>‡</sup>
Diffuse			0 <sup>‡</sup>	20 <sup>‡</sup>
Intestinal metaplasia				
Present	27	36	31	28
Absent	8	11	4	11
Mucosal atrophy				
Present	11 <sup>§</sup>	28 <sup>§</sup>	28	35
Absent	24 <sup>§</sup>	19 <sup>§</sup>	7	4
H. pylori infection				
Present	23	30	32	31
Absent	12	17	3	8

\**P* = 0.003; <sup>†</sup>*P* < 0.001; <sup>‡</sup>*P* < 0.001; <sup>§</sup>*P* = 0.01.

verse, 5'-CCTGTTCCCACTCATACAGG-3') as described above. All mutations were verified in both the sense and anti-sense directions.

### *K-ras* Oncogene Mutation Analysis

The first exon of *K-ras* was amplified in a 50- $\mu$ l volume using the reaction mixture described above with oligonucleotide primers (5'-GGCCGGTAGTGTATTAACCTTATGTGTGACAT-3' and 5'-CCGCGGCCGCGGCCAAAA-CAAGATTTACCTCTATTGTTGG-3'). PCR products were purified as described. The purified PCR products were sequenced using ABI PRISM BigDye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) with an internal primer 5'-ATTCGTCCACAAAATGAT-3'. The sequencing reactions were run on an ABI PRISM 3700 DNA Analyzer (Applied Biosystems). The data were collected and analyzed using Applied Biosystems sequencing software, according to the manufacturer's protocols.

### Microsatellite Instability Analysis

MSI status was determined by five fluorescently labeled PCR amplifications using fluorescent dye-labeled for-

ward primer and unlabeled reverse primer (BAT-25, BAT-26, D2S123, D5S346, and D17S250). The forward oligonucleotide was end-labeled with 6-FAM (Applied Biosystems). PCR was performed in 15- $\mu$ l volumes containing 40 ng of DNA, 9  $\mu$ l ABI Prism True Allele PCR Premix (Applied Biosystems), 5 pmol of 6-FAM-labeled forward primer, and 10 pmol of unlabeled reverse primer. PCR was performed using the following cycling conditions: denaturation at 95°C for 6 minutes, 45 cycles of 94°C for 45 seconds, 55°C for 45 seconds, 72°C for 1 minute, and extension at 72°C for 30 minutes. The PCR product was diluted further with 30  $\mu$ l of H<sub>2</sub>O, and a 1.0  $\mu$ l aliquot of each diluted fluorescent-labeled PCR product was combined with 12  $\mu$ l of formamide and 0.5  $\mu$ l of Genescan 400HD (ROX) size standard (Applied Biosystems). The samples were then capillary electrophoresed on an ABI 3700 DNA Analyzer using GeneScan Analysis software (Applied Biosystems). Allelic shift (MSI) of a microsatellite marker was defined by the presence of at least one additional band in the DNA from tumor or invasive carcinoma that was not present in the control normal DNA. A specimen was considered as MSI-high (MSI-H) when at least two markers showed allelic shift or MSI-low (MSI-L) when only one marker was shifted.

**Table 2.** *APC*,  $\beta$ -*catenin*, and *K-ras* Mutations in Gastric Adenomas, Flat Dysplasias, and Adenocarcinomas

	<i>APC</i>	$\beta$ - <i>catenin</i>	<i>K-ras</i>
Adenoma/dysplasia without carcinoma ( <i>n</i> = 82)	76% (59/78)**†	0% (0/19)	5% (4/82)
Polypoid adenoma ( <i>n</i> = 35)	77% (24/31)	0% (0/7)	9% (3/35)
Flat dysplasia ( <i>n</i> = 47)	74% (35/47)	0% (0/12)	2% (1/47)
Adenoma/dysplasia associated with carcinoma ( <i>n</i> = 35)	3% (1/30)*	0% (0/35)	0% (0/32)
Adenocarcinoma ( <i>n</i> = 74)	4% (3/69)†	0% (0/74)	1% (1/71)
Intestinal type ( <i>n</i> = 54)	4% (2/49)	0% (0/54)	2% (1/51)
with adenoma/dysplasia ( <i>n</i> = 35)	7% (2/30)	0% (0/35)	0% (0/32)
without adenoma/dysplasia ( <i>n</i> = 19)	0% (0/19)	0% (0/19)	5% (1/19)
Diffuse type ( <i>n</i> = 20)	5% (1/20)	0% (0/20)	0% (0/20)

\**P* < 0.000001; †*P* < 0.000001.

### Statistical Analysis


Fisher's exact test was used to compare differences in clinical or pathological characteristics, gene mutation, and MSI phenotype. A *P* value of <0.05 was considered statistically significant.

### Results

#### Somatic Mutations of *APC*, $\beta$ -*Catenin*, and *K-ras* Genes

Somatic *APC* mutations were more frequent in gastric adenomas and flat dysplasia without carcinoma (76%, 59 of 78) than in adenocarcinomas (4%, 3 of 69; *P* < 0.000001) or in adenomas/dysplasias associated with adenocarcinoma (3%, 1 of 30; *P* < 0.000001) (Table 2). There was no difference in the *APC* mutation rate between polypoid adenomas (77%, 24 of 31) and flat dysplasias (74%, 35 of 47). Similarly, there was no difference in the *APC* mutation rate between adenocarcinomas associated with adenoma/dysplasia (7%, 2 of 30) and adenocarcinomas without associated adenoma/dysplasia (3%, 1 of 39). Two adenocarcinomas associated with adjacent adenoma/dysplasia had *APC* mutations. One was a frameshift mutation (4-bp deletion of TCTC spanning codons 1464 to 1465) observed in both the carcinoma and adenoma/dysplasia components, and the other was a frame shift mutation (1-bp insertion of A in a poly(A) tract spanning codons 1554 to 1556) detected only in the carcinoma component not in the adenoma/dysplasia component. There was no correlation between the presence of *APC* mutation and grade of dysplasia in flat dysplasia or adenoma (88% and 76% in low grade versus 61% and 80% in high grade, respectively, *P* = 0.4). The distribution of *APC* mutations is summarized in Figure 1. Seventy-nine percent (50 of 63) of *APC* mutations were frameshifts (26 deletions and 24 insertions), and 21% (13 of 63) were nonsense point mutations resulting in truncation of the *APC* gene product. An insertion of A into the poly(A) tract at codons 1554 to 1556 was the most common (42%, 21 of 50) of the frameshift mutations. There were no significant associations between *APC* mutations and other clinicopathological parameters. No  $\beta$ -*catenin* mutations were detected in adenocarcinomas (*n* = 74), adenomas (*n* = 10), or dysplasia (*n* = 14) without *APC* mutation.

*K-ras* mutations were detected in 5% (4 of 82) of gastric adenomas/dysplasia without carcinoma, and 3% (1 of 39) of adenocarcinoma without associated adenoma/dysplasia, but were not found in adenocarcinoma with associated adenoma/dysplasia (*n* = 32). Only one gastric adenoma had both an activating codon 12 *K-ras*



**Figure 1.** Somatic *APC* gene mutations in gastric adenomas/dysplasias and adenocarcinomas. **A:** Summary of the *APC* gene mutations in the mutation cluster region. An insertion of A into the poly(A) tract at codons 1554 to 1556 is the most common mutation. **B:** An insertion of T (asterisk) at codon 1556 (adenoma 1), and an insertion of A (asterisk) into the poly(A) tract (bracket with arrow) at codons 1554 to 1556 (adenoma 2). In adenoma 2, the absence of normal sequence also indicates loss of the nonmutated *APC* allele. Adenoma 3 has normal *APC* sequence.

**Table 3.** APC Mutation and Microsatellite Instability (MSI) Status in Gastric Tumors with *K-ras* Mutation

No.	Histologic grade/type	<i>K-ras</i> mutation			APC mutation	MSI status
		Codon	Nucleotide change	Amino acid change		
1	Dysplasia, HG	12	GGT→GAT	Gly→Asp	–	MSI-S
2	Adenoma, LG	12	GGT→GCT	Gly→Ala	ND	MSI-L
3	Adenoma, HG	12	GGT→GAT	Gly→Asp	+	MSI-L
4	Adenoma, HG	12	GGT→GCT	Gly→Ala	ND	MSI-S
5	Adenocarcinoma intestinal-type	12	GGT→GAT	Gly→Asp	–	MSI-H

HG, high grade; LG, low grade; ND, not done; MSI-S, MSI stable phenotype; MSI-L, MSI-low phenotype; MSI-H, MSI-high phenotype.

mutation and a frame shift mutation of the *APC* gene (Table 3).

### Microsatellite Instability

MSI-H phenotype was more frequent in gastric adenoma/dysplasia associated with carcinoma (17%, 6 of 35) than in adenoma/dysplasia without carcinoma (3%, 2 of 75;  $P = 0.01$ ) (Table 4). Two of 30 adenomas, but none of 45 flat dysplasias had MSI-H phenotype. MSI-H phenotype was also more frequent in intestinal-type adenocarcinoma (20%, 11 of 54) than in diffuse-type (0%, 0 of 20;  $P = 0.03$ ). There was no difference in the frequency of MSI-L phenotype between gastric adenoma/dysplasia associated with carcinoma (9%, 3 of 35) and adenomas/dysplasia without carcinoma (9%, 7 of 75); or between intestinal type adenocarcinoma and diffuse type [6% (3 of 54) versus 5% (1 of 20), respectively].

MSI phenotype was not correlated with grade of dysplasia. Among two MSI-L flat gastric dysplasias, one was high-grade dysplasia and one was low-grade dysplasia. Similarly, among two MSI-H and five MSI-L adenomas, three were high-grade dysplasia and four were low-grade dysplasia. Among adenocarcinomas associated with adenoma/dysplasia, MSI+ phenotype was present in both the carcinoma and adenoma/dysplasia components in five cases (four MSI-H and one MSI-L), in carcinoma alone in four cases (two MSI-H and two MSI-L), and in adenoma/dysplasia alone in four cases (two MSI-H and two MSI-L). Three of five MSI+ cases had a different allelic shift pattern between the carcinoma and adjacent adenoma/dysplasia components (Figure 2).

### Correlation between APC, K-ras, and Microsatellite Instability Status

There was an inverse correlation between the presence of MSI-H and the presence of *APC* gene mutations. *APC* gene mutations were present in six of nine (67%) gastric adenomas/dysplasias with MSI-L phenotype, but in none of the eight adenomas/dysplasia with MSI-H phenotype ( $P = 0.009$ ) (Table 5). The three MSI-L adenomas/dysplasias without *APC* mutations were associated with adenocarcinomas. No *APC* mutations were detected in any of the 15 MSI+ (11 MSI-H and 4 MSI-L) gastric adenocarcinomas.

There was no association between *K-ras* mutation and MSI phenotype. Among five tumors with *K-ras* mutations, two were MSI-S, two were MSI-L, and one was MSI-H (Table 3).

### Discussion


Gastric dysplastic lesions such as polypoid adenomas or flat dysplasia are frequently seen in patients with chronic atrophic gastritis and intestinal metaplasia. Intestinal-type gastric carcinomas also typically arise in a background of atrophic gastritis with intestinal metaplasia.<sup>18</sup> Although gastric carcinomas can arise from pre-existing dysplastic lesions, only a subset of gastric carcinoma has identifiable preneoplastic lesions.<sup>29–31</sup> The adenoma-carcinoma sequence typically seen in colorectal carcinoma does not seem to be a major pathway in gastric carcinogenesis. This issue is further complicated by the

**Table 4.** Microsatellite Instability (MSI) in Gastric Adenoma/Dysplasia and Adenocarcinoma

	MSI (+)	MSI-H	MSI-L
Adenoma/dysplasia without carcinoma ( $n = 82$ )	12% (9/75)	3% (2/75)*	9% (7/75)
Polypoid adenoma ( $n = 35$ )	23% (7/30)	7% (2/30)	17% (5/30)
Flat dysplasias ( $n = 47$ )	4% (2/45)	0% (0/45)	4% (2/45)
Adenoma/dysplasia associated with carcinoma ( $n = 35$ )	26% (9/35)	17% (6/35)*	9% (3/35)
Adenocarcinoma ( $n = 74$ )			
Intestinal type ( $n = 54$ )	26% (14/54)	20% (11/54)†	6% (3/54)
with adenoma/dysplasia ( $n = 35$ )	26% (9/35)	17% (6/35)	9% (3/35)
without adenoma/dysplasia ( $n = 19$ )	26% (5/19)	26% (5/19)	0% (0/19)
Diffuse type ( $n = 20$ )	5% (1/20)	0% (0/20)†	5% (1/20)

\* $P = 0.01$ ; † $P = 0.03$ .

MSI (+) includes both MSI-H and MSI-L phenotypes; MSI-H, MSI high phenotype; MSI-L, MSI low phenotype.



**Figure 2.** Microsatellite instability in gastric adenocarcinoma and the associated adenoma/dysplasia. The adenoma/dysplasia component shows a different allelic shift pattern in all five markers (D2S123, D5S346, D17S250, BAT25, and BAT26) as compared to the adenocarcinoma component.

facts that only a small subset of gastric adenoma or dysplastic lesions eventually progress to carcinoma.

The reason for lack of neoplastic progression in the majority of gastric adenomas and dysplastic lesions is not clear. *APC* gene mutations have been previously reported in up to 40% of gastric adenomas but only rarely in gastric adenocarcinomas.<sup>3,4,24-26,36,37</sup> The presence of frequent somatic *APC* mutations in gastric adenoma but not in gastric carcinoma suggests that there is a different genetic pathway for the pathogenesis of adenoma and carcinoma. However, in previous studies only isolated adenomas and gastric carcinomas have been studied. Gastric adenoma/dysplasia lesions associated with adenocarcinomas have not been studied in detail for the presence of *APC* mutation.<sup>3,4,25,26,36</sup> In most cases, the adenocarcinoma can be assumed to have arisen within the dysplasia or adenoma. If the *APC* gene plays any role in the pathogenesis of adenocarcinomas arising from pre-existing adenoma/dysplasia, *APC* gene mutations should be detected in both adenoma/dysplasia and adenocarcinoma components, similar to the frequency of *APC* gene mutations in adenomas or dysplasias without adenocarcinoma. Our study demonstrates that *APC* mutations are frequent in sporadic gastric adenomas and dysplasias, but only rarely in adenocarcinomas. This rare presence of *APC* mutations was true for both adenocarcinomas with or without associated adenoma/dysplasia. The findings in this study therefore strongly indicate that *APC* gene mutations play an important role in the pathogenesis of gastric adenoma and dysplasia, but have only a limited role in the pathogenesis of gastric adenocarcinomas. *β-catenin* gene mutations have previously been reported in 5% (4 of 77) to 16% (7 of 43) of gastric adenocarcinomas from the Korean population.<sup>8,38</sup> In contrast, we found no *β-catenin* gene mutations in 54 intestinal and 20 diffuse type adenocarcinomas. The reason for this discrepancy is not clear.


**Table 5.** *APC* Gene Mutation Status in MSI+ Gastric Adenoma/Dysplasia

	MSI-H	MSI-L
<i>APC</i> Gene Mutation		
Present	0% (0/8)*	67% (6/9)*
Absent	100% (8/8)*	33% (3/9)*

\*P = 0.009.

MSI-H, microsatellite instability high phenotype; MSI-L, microsatellite instability low phenotype.

Our results also suggest that *APC* gene mutation status could predict the biological behavior of individual gastric adenoma/dysplasia lesions (Figure 3). Gastric adenomas/dysplasias with *APC* gene mutations only rarely progress to adenocarcinoma. This corroborates the clinical observation that only 11 to 40% of adenomas/dysplasias can progress to carcinoma.<sup>29-31</sup> This is contradictory to the role of the *APC* gene in colorectal carcinogenesis, in which it is regarded as a gatekeeper gene and is involved in the vast majority of colorectal carcinomas.<sup>39</sup> Because we only sequenced the mutation cluster region of the *APC* gene, we cannot exclude *APC* mutations outside this region. It is possible that *APC* gene mutations in adenocarcinomas either associated or not associated with adenoma/dysplasia are different from sporadic gastric adenomas or dysplasias, and are not present within the mutation cluster region we have sequenced. However, the presence of only rare *APC* gene mutations in gastric carcinomas in previously published studies further corroborates our results.<sup>40</sup> In addition, we have previously shown frequent somatic second-hit of *APC* genes in FAP-associated gastric fundic gland polyps.<sup>41</sup> Foveolar dysplasia can present in up to 25% of FAP-associated fundic gland polyps, but rare occurrence of adenocarcinomas in FAP-associated fundic gland polyps. Therefore, *APC* gene mutations seem to have a different biological behavior in the stomach as compared to the colorectum, and gastric adenomas/dysplasia with *APC* mutations only rarely progress to adenocarcinomas.



**Figure 3.** Role of *APC* gene and MSI in gastric adenoma/dysplasia-carcinoma sequence. Adenocarcinoma can arise *de novo* or from pre-existing adenoma/dysplasia. Adenomas or dysplasias with *APC* gene mutations rarely progress to adenocarcinoma, and have a different biological behavior as compared to adenomas or dysplasias with MSI.

Gastric dysplastic lesions can be divided into adenomas (with a polypoid configuration) or flat dysplasias based on growth pattern.<sup>32</sup> However, it is difficult to differentiate adenoma from flat dysplasia once adenocarcinoma has arisen from these pre-existing dysplastic lesions. Furthermore, genetic alterations of these two distinct morphological gastric dysplastic lesions (polypoid adenoma and flat dysplasia) have not been studied in detail. We found no difference in the frequency of *APC* mutations in gastric adenomas versus flat dysplasias. In the colorectum, *K-ras* mutations are associated with a polypoid growth pattern in colorectal adenomas and adenocarcinomas, and are more frequent in polypoid adenomas as compared to flat adenomas.<sup>42–44</sup> In contrast, in our study the prevalence of *K-ras* mutations was not different between polypoid adenomas and flat dysplasias in the stomach.

Microsatellite instability (MSI) because of DNA replication errors has been widely observed in a variety of sporadic tumors in addition to tumors associated with hereditary nonpolyposis colorectal cancer syndrome because of germ line mutations in mismatch repair genes.<sup>45–48</sup> MSI has been identified in 7 to 50% of gastric carcinomas with geographic variation in prevalence.<sup>49</sup> We found MSI-H phenotype in 11% (8 of 75) of gastric adenomas/dysplasias and in 20% (11 of 54) of gastric intestinal type adenocarcinomas, which are similar to previously published results; 21% (13 of 63) in gastric adenomas and 30% (19 of 63) in gastric carcinomas from the Korean population.<sup>46</sup> Similar to colorectal carcinomas, MSI-positive gastric carcinomas have distinct clinicopathological features including better prognosis, and prominent lymphoid infiltration. MSI-positivity is more common in intestinal type gastric carcinoma located in the antrum than in diffuse type carcinoma.<sup>50–53</sup> In the present study, we found a higher prevalence of MSI-H phenotype in adenoma/dysplasia associated with adenocarcinoma than adenomas not associated with adenocarcinoma, as previously reported.<sup>54</sup> Three of five MSI+ adenocarcinomas associated with adenoma/dysplasia components had a different allelic shift pattern between carcinoma and adjacent adenoma/dysplasia components. One explanation for this finding is that an adenocarcinoma acquires a different allelic size during progression of tumor from adenoma/dysplasia. This phenomenon has been described in MSI+ tumor cells.<sup>55</sup> However, the possibility of adenocarcinoma arising *de novo*, and not from the pre-existing adenoma/dysplasia cannot be completely excluded. MSI+ colorectal and pancreatic carcinomas have a distinct genetic profile with wild-type *K-ras* and lack of *p53* gene mutations.<sup>55–57</sup> Similarly, MSI-H gastric adenocarcinomas or adenomas/dysplasias also correlated with the absence of *APC* gene mutations in our study. In contrast, MSI-L gastric adenomas/dysplasias had frequent *APC* mutations.

In conclusion, our results demonstrate that somatic mutation of the *APC* gene plays an important role in the pathogenesis of gastric adenoma and dysplasia but has limited role in neoplastic progression to adenocarcinoma. In contrast, gastric adenomas or dysplasias without *APC* mutations may have a different biological behavior, and

are precursors of intestinal type of gastric adenocarcinomas. MSI-H can play an important role in a subset of adenocarcinomas arising from gastric adenomas/dysplasias without *APC* mutations.

## References

1. Rhyu MG, Park WS, Jung YJ, Choi SW, Meltzer SJ: Allelic deletions of MCC/APC and p53 are frequent late events in human gastric carcinogenesis. *Gastroenterology* 1994, 106:1584–1588
2. Kang GH, Kim CJ, Kim WH, Kang YK, Kim HO, Kim YI: Genetic evidence for the multicentric origin of synchronous multiple gastric carcinoma. *Lab Invest* 1997, 76:407–417
3. Horii A, Nakatsuru S, Miyoshi Y, Ichii S, Nagase H, Kato Y, Yanagisawa A, Nakamura Y: The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. *Cancer Res* 1992, 52:3231–3233
4. Nishimura K, Yokozaki H, Jaruma K, Kajiyama G, Tahara E: Alterations of the APC gene in carcinoma cell lines and precancerous lesions of the stomach. *Int J Oncol* 1995, 7:587–592
5. Arber N, Shapira I, Ratan J, Stern B, Hibshoosh H, Moshkowitz M, Gammon M, Fabian I, Halpern Z: Activation of c-K-ras mutations in human gastrointestinal tumors. *Gastroenterology* 2000, 118:1045–1050
6. Kihana T, Tsuda H, Hirota T, Shimosato Y, Sakamoto H, Terada M, Hirohashi S: Point mutation of c-Ki-ras oncogene in gastric adenoma and adenocarcinoma with tubular differentiation. *Jpn J Cancer Res* 1991, 82:308–314
7. Lee KH, Lee JS, Suh C, Kim SW, Kim SB, Lee JH, Lee MS, Park MY, Sun HS, Kim SH: Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. *Cancer* 1995, 75:2794–2801
8. Park WS, Oh RR, Park JY, Lee SH, Shin MS, Kim YS, Kim SY, Lee HK, Kim PJ, Oh ST, Yoo NJ, Lee JY: Frequent somatic mutations of the beta-catenin gene in intestinal-type gastric cancer. *Cancer Res* 1999, 59:4257–4260
9. Becker KF, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hoffer H: E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 1994, 54:3845–3852
10. Becker KF, Kremmer E, Eulitz M, Becker I, Handschuh G, Schuhmacher C, Muller W, Gabbert HE, Ochiai A, Hirohashi S, Hoffer H: Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. *Am J Pathol* 1999, 155:1803–1809
11. Gayther SA, Goringe KL, Ramus SJ, Huntsman D, Roviello F, Grehan N, Machado JC, Pinto E, Seruca R, Halling K, MacLeod P, Powell SM, Jackson CE, Ponder BA, Caldas C: Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. *Cancer Res* 1998, 58:4086–4089
12. Yokozaki H, Ito R, Nakamura H, Kuniyasu H, Taniyama K, Tahara E: Expression of CD44 abnormal transcripts in human gastric carcinomas. *Cancer Lett* 1994, 83:229–234
13. Kang GH, Shim YH, Ro JY: Correlation of methylation of the hMLH1 promoter with lack of expression of hMLH1 in sporadic gastric carcinomas with replication error. *Lab Invest* 1999, 79:903–909
14. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. *Acta Pathol Microbiol Scand* 1965, 64:31–49
15. Stadlander CT, Waterbor JW: Molecular epidemiology, pathogenesis and prevention of gastric cancer. *Carcinogenesis* 1999, 20:2195–2208
16. Tahara E, Semba S, Tahara H: Molecular biological observations in gastric cancer. *Semin Oncol* 1996, 23: 307–315
17. Chan AO, Luk JM, Hui WM, Lam SK: Molecular biology of gastric carcinoma: from laboratory to bedside. *J Gastroenterol Hepatol* 1999, 14:150–160
18. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process—First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. *Cancer Res* 1992, 52:6735–6740
19. Correa P, Shiao YH: Phenotypic and genotypic events in gastric carcinogenesis. *Cancer Res* 1994, 54(Suppl):1941s–1943s
20. Correa P: A human model of gastric carcinogenesis. *Cancer Res* 1988, 48:3554–3560

21. Solcia E, Fiocca R, Luginetti O, Villani L, Padovan L, Calistri D, Ranzani GN, Chiaravalli A, Capella C: Intestinal and diffuse gastric cancers arise in a different background of *Helicobacter pylori* gastritis through different gene involvement. *Am J Surg Pathol* 1996, 20(Suppl 1):S8–S22
22. Tahara E: Molecular mechanism of stomach carcinogenesis. *J Cancer Res Clin Oncol* 1993, 119:265–272
23. Hiyama E, Yokoyama T, Tatsumoto N, Hiyama K, Imamura Y, Murakami Y, Kodama T, Piatyszek MA, Shay JW, Matsuura Y: Telomerase activity in gastric cancer. *Cancer Res* 1995, 55:3258–3262
24. Maesawa C, Tamura G, Suzuki Y, Ogasawara S, Sakata K, Kashiwaba M, Satodate R: The sequential accumulation of genetic alterations characteristic of the colorectal adenoma-carcinoma sequence does not occur between gastric adenoma and adenocarcinoma. *J Pathol* 1995, 176:249–258
25. Nakatsuru S, Yanagisawa A, Furukawa Y, Ichii S, Kato Y, Nakamura Y, Horii A: Somatic mutations of the APC gene in precancerous lesion of the stomach. *Hum Mol Genet* 1993, 2:1463–1465
26. Tamura G, Maesawa C, Suzuki Y, Tamada H, Satoh M, Ogasawara S, Kashiwaba M, Satodate R: Mutations of the APC gene occur during early stages of gastric adenoma development. *Cancer Res* 1994, 54:1149–1151
27. Rugge M, Farinati F, Di Mario F, Baffa R, Valiante F, Cardin F: Gastric epithelial dysplasia: a prospective multicenter follow-up study from the Interdisciplinary Group on Gastric Epithelial Dysplasia Multicenter Study. *Hum Pathol* 1991, 22:1002–1008
28. Rugge M, Farinati F, Baffa R, Sonego F, Di Mario F, Leandro G, Valiante F: Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. *Interdisciplinary Group on Gastric Epithelial Dysplasia. Gastroenterology* 1994, 107:288–296
29. Kolodziejczyk P, Yao T, Oya M, Nakamura S, Utsunomiya T, Ishikawa T, Tsuneyoshi M: Long-term follow-up study of patients with gastric adenomas with malignant transformation. An immunohistochemical and histochemical analysis *Cancer* 1994, 74:2896–2907
30. Orłowska J, Jarosz D, Pachlewski J, Butruk E: Malignant transformation of benign epithelial gastric polyps. *Am J Gastroenterol* 1995, 90:2152–2159
31. Kamiya T, Morishita T, Asakura H, Miura S, Munakata Y, Tsuchiya M: Long-term follow-up study on gastric adenoma and its relation to gastric protruded carcinoma. *Cancer* 1982, 50:2496–2503
32. Genta RM, Rugge M: Gastric precancerous lesions; heading for an international consensus. *Gut* 1999, 45(Suppl):I5–I8
33. Sobin LH: *International Union Against Cancer. Stomach. TNM Classification of Malignant Tumours*, ed 5. Edited by LH Sobin, C Wittekind. New York, Wiley-Liss, 1997, pp 59–62
34. Stolte M, Meining A: The updated Sydney system: classification and grading of gastritis as the basis of diagnosis and treatment. *Can J Gastroenterol* 2001, 15:591–598
35. Goelz SE, Hamilton SR, Vogelstein B: Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. *Biochem Biophys Res Commun* 1985, 130:118–126
36. Nakatsuru S, Yanagisawa A, Ichii S, Tahara E, Kato Y, Nakamura Y, Horii A: Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. *Hum Mol Genet* 1992, 1:559–563
37. Powell SM, Cummings OW, Mullen JA, Asghar A, Fuga G, Piva P, Minacci C, Megha T, Tosi P, Jackson CE: Characterization of the APC gene in sporadic gastric adenocarcinomas. *Oncogene* 1996, 12:1953–1959
38. Woo DK, Kim HS, Lee HS, Kang YH, Yang HK, Kim WH: Altered expression and mutation of  $\beta$ -catenin gene in gastric carcinomas and cell lines. *Int J Cancer* 2001, 95:108–113
39. Peifer M, Polakis P: Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus. *Science* 2000, 287:1606–1609
40. Beroud C, Soussi T: APC gene: database of germline and somatic mutations in human tumors and cell lines. *Nucleic Acids Res* 1996, 24:121–124
41. Abraham SC, Nobukawa B, Giardiello FM, Hamilton SR, Wu TT: Fundic gland polyps in familial adenomatous polyposis: neoplasms with frequent somatic adenomatous polyposis coli gene alterations. *Am J Pathol* 2000, 157:747–754
42. Chiang JM, Chou YH, Chou TB: K-ras codon 12 mutation determines the polypoid growth of colorectal cancer. *Cancer Res* 1998, 58:3289–3293
43. Yashiro M, Carethers JM, Laghi L, Saito K, Slezak P, Jaramillo E, Rubio C, Koizumi K, Hirakawa K, Boland CR: Genetic pathways in the evolution of morphologically distinct colorectal neoplasms. *Cancer Res* 2001, 61:2676–2683
44. van Wyk R, Slezak P, Hayes VM, Buys CH, Kotze MJ, de Jong G, Rubio C, Dolk A, Jaramillo E, Koizumi K, Grobbelaar JJ: Somatic mutations of the APC, KRAS, and TP53 genes in nonpolypoid colorectal adenomas *Genes Chromosom Cancer* 2000, 27:202–208
45. Keller G, Rudelius M, Vogelsang H, Grimm V, Wilhelm MG, Mueller J, Siewert JR, Hofler H: Microsatellite instability and loss of heterozygosity in gastric carcinoma in comparison to family history. *Am J Pathol* 1998, 152:1281–1289
46. Kim HS, Woo DK, Bae SI, Kim YI, Kim WH: Microsatellite instability in the adenoma-carcinoma sequence of the stomach. *Lab Invest* 2000, 80:57–64
47. Leung WK, Kim JJ, Kim JG, Graham DY, Sepulveda AR: Microsatellite instability in gastric intestinal metaplasia in patients with and without gastric cancer. *Am J Pathol* 2000, 156:537–543
48. Ottini L, Palli D, Falchetti M, D'Amico C, Amorosi A, Saieva C, Calzolari A, Cimoli F, Tatarelli C, De Marchis L, Masala G, Mariani-Costantini R, Cama A: Microsatellite instability in gastric cancer is associated with tumor location and family history in a high-risk population from Tuscany. *Cancer Res* 1997, 57:4523–4529
49. Sepulveda AR, Santos AC, Yamaoka Y, Wu L, Gutierrez O, Kim JG, Graham DY: Marked differences in the frequency of microsatellite instability in gastric cancer from different countries. *Am J Gastroenterol* 1999, 94:3034–3038
50. Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ, Chang MC, Sheu JC, Lin JT: Distinct clinicopathologic and genetic profiles in sporadic gastric cancer with different mutator phenotypes. *Genes Chromosom Cancer* 2000, 27:403–411
51. Wu MS, Lee CW, Shun CT, Wang HP, Lee WJ, Sheu JC, Lin JT: Clinicopathological significance of altered loci of replication error and microsatellite instability-associated mutations in gastric cancer. *Cancer Res* 1998, 58:1494–1497
52. Ohmura K, Tamura G, Endoh Y, Sakata K, Takahashi T, Motoyama T: Microsatellite alterations in differentiated-type adenocarcinomas and precancerous lesions of the stomach with special reference to cellular phenotype. *Hum Pathol* 2000, 31:1031–1035
53. Chong JM, Fukayama M, Hayashi Y, Takizawa T, Koike M, Konishi M, Kikuchi-Yanoshita R, Miyaki M: Microsatellite instability in the progression of gastric carcinoma. *Cancer Res* 1994, 54:4595–4597
54. Isogaki J, Shinmura K, Yin W, Arai T, Koda K, Kimura T, Kino I, Sugimura H: Microsatellite instability and K-ras mutations in gastric adenomas, with reference to associated gastric cancers. *Cancer Detect Prev* 1999, 23:204–214
55. Shibata D: Molecular tumor clocks and dynamic phenotype. *Am J Pathol* 1997, 151:643–646
56. Ruschoff J, Dietmaier W, Luttgies J, Seitz G, Bocker T, Zirngibl H, Schlegel J, Schackert HK, Jauch KW, Hofstaedter F: Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics. *Am J Pathol* 1997, 150:1815–1825
57. Goggins M, Offerhaus GJA, Hilgers W, Griffin CA, Shekher M, Tang D, Sohn TA, Yeo CJ, Kern SE, Hruban RH: Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology: poor differentiation, a syncytial growth pattern, and pushing borders suggests RER+. *Am J Pathol* 1998, 152:1501–1507